Sally John, Ph.D.


Sally John, PhD, is the Head of Translational Biology within Research and Development (R&D) at Biogen. She joined Biogen in 2014 as Vice President of the Genetics and Computational Biology groups, She is committed to increasing the probability of success in R&D through the use of human genetics combined with robust translational pre-clinical models and end-points. She has held roles of increasing responsibility within Research in AstraZeneca and Development in Pfizer. Sally has a PhD in Molecular Biology from the University of Manchester, UK and post-doctoral training in Genetic Epidemiology.  P

HLTH does not sell or provide any personal data (including email, phone, address) to any third parties and we never will. Any communication that pretends to be HLTH or any third parties selling purported lists, discounted rooms, or any product/services are NOT AFFILIATED with HLTH and are to be considered FRAUD.

Upcoming Event Dates

2024 | ViVE: Feb 25-28; HLTH Europe: Jun 17-20; HLTH US: Oct 20-23

2025 | ViVE: Feb 16-19; HLTH US: Oct 19-22

2026 | HLTH US: Nov 15-18

2027 | HLTH US: Oct 17-20

© 2024 HLTH, INC. All Rights Reserved